Scienmag

NOVEMBER 13, 2021

A regular, affordable antibiotic treatment significantly reduced the risk of underlying rheumatic heart disease progression in children and adolescents, according to a new study. Credit: Roman Nguyen A regular, affordable antibiotic treatment significantly reduced the risk of underlying rheumatic heart disease progression in children and adolescents, according to a new study.

Research 90

Research Medicine 90

Drug Patent Watch

NOVEMBER 13, 2021

ASACOL HD (mesalamine) Apil Patent: 9,089,492 Expiration: Nov 15, 2021 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or…. The post Drug Patent Expirations for the Week of November 14, 2021 appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40

Drugs 40

Scienmag

NOVEMBER 13, 2021

Intermittent fasting may not only be a hot dieting trend, but it also has broader health benefits, including helping to fight inflammation, according to a new study from researchers at the Intermountain Healthcare Heart Institute in Salt Lake City. Credit: Intermountain Healthcare Intermittent fasting may not only be a hot dieting trend, but it also […].

Research 88

Research Medicine 88

BioTech 365

NOVEMBER 13, 2021

NewAmsterdam Pharma Presents Full Results from Phase 2 ROSE Study of Obicetrapib in Patients with Dyslipidemia NewAmsterdam Pharma Presents Full Results from Phase 2 ROSE Study of Obicetrapib in Patients with Dyslipidemia New positive data for obicetrapib in patients with … Continue reading →

52

52

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Clinical Research

Scienmag

NOVEMBER 13, 2021

The COVID-19 pandemic has not only affected the physical health of millions of Americans, but it’s also taken a toll on the country’s mental health. Credit: Intermountain Healthcare The COVID-19 pandemic has not only affected the physical health of millions of Americans, but it’s also taken a toll on the country’s mental health. A new […].

78

78

BioTech 365

NOVEMBER 13, 2021

Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Cancers at Society for Immunotherapy of Cancer (SITC) Annual Meeting Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Cancers at Society for … Continue reading →

40

40

BioTech 365

NOVEMBER 13, 2021

Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and … Continue reading →

40

40

BioTech 365

NOVEMBER 13, 2021

CG Oncology Presents Preliminary Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin CG Oncology Presents Preliminary Phase 2 Data with CG0070 in Combination with KEYTRUDA® (pembrolizumab) in Non-Muscle-Invasive Bladder Cancer … Continue reading →

40

40

BioTech 365

NOVEMBER 13, 2021

Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS) Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS) In an … Continue reading →

40

40

BioTech 365

NOVEMBER 13, 2021

NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer Annual Meeting NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer … Continue reading →

Research 40

Research 40

Advertisement

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

Clinical Trials

BioTech 365

NOVEMBER 13, 2021

Veracyte Announces New Data on Immuno-Oncology Offerings Presented at SITC 2021 Veracyte Announces New Data on Immuno-Oncology Offerings Presented at SITC 2021 Brightplex technology is designed to enable biopharmaceutical researchers to assess the complex tumor micro-environment to aid in development … Continue reading →

Development 52

Development Research 52

BioTech 365

NOVEMBER 13, 2021

Triumvira Announces Data from Gastric Cancer Preclinical Study to be Presented at SITC Annual Meeting Triumvira Announces Data from Gastric Cancer Preclinical Study to be Presented at SITC Annual Meeting Novel CLDN18.2-TAC T cell candidate effectively eradicated Claudin 18.

52

52

BioTech 365

NOVEMBER 13, 2021

Seven and Eight Biopharma’s BDB001 in Combination with an anti-PD-L1 mAb Shows Favorable Safety and Clinical Responses in Interim Phase 1 Data Presented at the 2021 SITC Annual Meeting Seven and Eight Biopharma’s BDB001 in Combination with an anti-PD-L1 mAb … Continue reading →

52

52

BioTech 365

NOVEMBER 13, 2021

Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021 Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the … Continue reading →

52

52

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Clinical Supply